Traumatic brain injury (TBI) is a leading cause of death and disability, particularly among the young. Despite this, no disease-specific treatments exist. Recently, blood–brain barrier disruption and parenchymal fibrinogen deposition have been reported in acute traumatic brain injury and in long-term survival; however, their contribution to the neuropathology of TBI remains unknown. The presence of fibrinogen—a well-documented activator of microglia/macrophages—may be associated with neuroinflammation, and neuronal/axonal injury. To test this hypothesis, cases of human TBI with survival times ranging from 12 h to 13 years (survival <2 months, n = 15; survival >1 year, n = 6) were compared with uninjured controls (n = 15). Tissue was selected from the frontal lobe, temporal lobe, corpus callosum, cingulate gyrus, and brainstem, and the extent of plasma protein (fibrinogen and immunoglobulin G [IgG]) deposition, microglial/macrophage activation (CD68 and ionized calcium-binding adapter molecule 1 [Iba-1] immunoreactivity), neuronal density, and axonal transport impairment (β-amyloid precursor protein [βAPP] immunoreactivity) were assessed. Quantitative analysis revealed a significant increase in parenchymal fibrinogen and IgG deposition following acute TBI compared with long-term survival and control. Fibrinogen, but not IgG, was associated with microglial/macrophage activation and a significant reduction in neuronal density. Perivascular fibrinogen deposition also was associated with microglial/macrophage clustering and accrual of βAPP in axonal spheroids, albeit rarely. These findings mandate the future exploration of causal relationships between fibrinogen deposition, microglia/macrophage activation, and potential neuronal loss in acute TBI.
Get full access to this article
View all access options for this article.
References
1.
SawM.M., ChamberlainJ., BarrM., MorganM.P.G., BurnettJ.R., and HoK.M. (2014). Differential disruption of blood–brain barrier in severe traumatic brain injury. Neurocrit. Care, 20, 209–216.
2.
HayJ.R., JohnsonV.E., YoungA.M.H., SmithD.H., and StewartW. (2015). Blood-brain Bbarrier disruption is an early event that may persist for many years after traumatic brain injury in Hhumans. J. Neuropathol. Exp. Neurol., 74, 1147–1157.
3.
PeetersW., van den BrandeR., PolinderS., BrazinovaA., SteyerbergE.W., LingsmaH.F., and MaasA.I.R. (2015). Epidemiology of traumatic brain injury in Europe. Acta Neurochir. (Wien) 157, 1683–1696.
4.
KinoshitaK. (2016). Traumatic brain injury: pathophysiology for neurocritical care. J. Intensive Care, 4, 1028–10.
5.
MarmarouA., NicholsJ., BurgessJ., NewellD., TrohaJ., BurnhamD., and PittsL. (1999). Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. J. Neurotrauma, 16, 431–444.
6.
MorrisG.F., BullockR., MarshallS.B., MarmarouA., MaasA., and MarshallL.F. (1999). Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. J. Neurosurg., 91, 737–743.
7.
EdwardsP., ArangoM., BalicaL., CottinghamR., El-SayedH., FarrellB., FernandesJ., GogichaisviliT., GoldenN., HartzenbergB., HusainM., UlloaM.I., JerbiZ., KhamisH., KomolafeE., LaloëV., LomasG., LudwigS., MazairacG., Muñoz SanchézM., deL.A., NasiL., OlldashiF., PlunkettP., RobertsI., SandercockP., ShakurH., SolerC., StockerR., SvobodaP., TrenklerS., VenkataramanaN.K., WasserbergJ., YatesD., and YutthakasemsuntS.; CRASH trial collaborators. (2005). Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet, 365, 1957–1959.
8.
ShlosbergD., BeniflaM., KauferD., and FriedmanA. (2010). Blood–brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol, 6, 393–403.
9.
TomkinsO., ShelefI., KaizermanI., EliushinA., AfawiZ., MiskA., GidonM., CohenA., ZumstegD., and FriedmanA. (2008). Blood-brain barrier disruption in post-traumatic epilepsy. J. Neurol. Neurosurg. Psychiatry, 79, 774–777.
10.
ChodobskiA., ZinkB.J., and Szmydynger-ChodobskaJ. (2011). Blood–brain barrier pathophysiology in traumatic brain injury. Transl Stroke Res, 2, 492–516.
11.
FlickM.J., DuX., WitteD.P., JirouškováM., SolovievD.A., BusuttilS.J., PlowE.F., and DegenJ.L. (2004). Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J. Clin. Invest., 113, 1596–1606.
12.
DavalosD., RyuJ.K., MerliniM., BaetenK.M., Le MoanN., PetersenM.A., DeerinckT.J., SmirnoffD.S., BedardC., HakozakiH., Gonias MurrayS., LingJ.B., LassmannH., DegenJ.L., EllismanM.H., and AkassoglouK. (2012). Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat. Commun., 3, 1227.
13.
ViggarsA.P., WhartonS.B., SimpsonJ.E., MatthewsF.E., BrayneC., SavvaG.M., GarwoodC., DrewD., ShawP.J., and InceP.G. (2011). Alterations in the blood brain barrier in ageing cerebral cortex in relationship to Alzheimer-type pathology: a study in the MRC-CFAS population neuropathology cohort. Neurosci. Lett., 505, 25–30.
14.
Cortes-CanteliM., PaulJ., NorrisE.H., BronsteinR., AhnH.J., ZamolodchikovD., BhuvanendranS., FenzK.M., and StricklandS. (2010). Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron, 66, 695–709.
15.
LiuJ.Y.W., ThomM., CatarinoC.B., MartinianL., Figarella-BrangerD., BartolomeiF., KoeppM., and SisodiyaS.M. (2012). Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain, 135, 3115–3133.
16.
AkassoglouK., YuW.M., AkpinarP., and StricklandS. (2002). Fibrin inhibits peripheral nerve remyelination by regulating Schwann cell differentiation. Neuron, 33, 861–875.
17.
RyuJ.K. and McLarnonJ.G. (2009). A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J. Cell. Mol. Med., 13, 2911–2925.
18.
AkassoglouK., AdamsR.A., BauerJ., MercadoP., TsevelekiV., LassmannH., ProbertL., and StricklandS. (2004). Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A., 101, 6698–6703.
19.
PatibandlaP.K., TyagiN., DeanW.L., TyagiS.C., RobertsA.M., and LominadzeD. (2009). Fibrinogen induces alterations of endothelial cell tight junction proteins. J. Cell. Physiol., 221, 195–203.
WebsterK.M., SunM., CrackP., O'BrienT.J., ShultzS.R., and SempleB.D. (2017). Inflammation in epileptogenesis after traumatic brain injury. J. Neuroinflammation, 14, 1–17.
22.
MalecJ.F., BrownA.W., LeibsonC.L., FlaadaJ.T., MandrekarJ.N., DiehlN.N., and PerkinsP.K. (2007). The Mayo Classification System for Traumatic Brain Injury Severity. J. Neurotrauma, 24, 1417–1424.
23.
TeasdaleG., and JennettB. (1974). Assessment of coma and impaired consciousness. A practical scale. Lancet, 2, 81–84.
24.
GillS.K., IshakM., and RylettR.J. (2005). Exposure of nuclear antigens in formalin-fixed, paraffin-embedded necropsy human spinal cord tissue: detection of NeuN. J. Neurosci. Methods, 148, 26–35.
YatesR.L., EsiriM.M., PalaceJ., JacobsB., PereraR., and DeLucaG.C. (2017). Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex. Ann. Neurol., 82, 259–270.
27.
JohnsonV.E., StewartJ.E., BegbieF.D., TrojanowskiJ.Q., SmithD.H., and StewartW. (2013). Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain, 136, 28–42.
28.
GeddesJ.F., VowlesG.H., BeerT.W., and EllisonD.W. (1997). The diagnosis of diffuse axonal injury: implications for forensic practice. Neuropathol. Appl. Neurobiol., 23, 339–347.
29.
HayashiT., AgoK., NakamaeT., HigoE., and OgataM. (2015). Two different immunostaining patterns of beta-amyloid precursor protein (APP) may distinguish traumatic from nontraumatic axonal injury. Int. J. Legal Med., 129, 1085–1090.
30.
KorzhevskiiD.E. and KirikO.V. (2016). Brain Microglia and Microglial Markers. Neurosci. Behav. Physi., 46, 284–290.
31.
KlatzoI. (1967). Presidental address. Neuropathological aspects of brain edema. J. Neuropathol. Exp. Neurol., 26, 1–14.
32.
Ünal-ÇevikI., KılınçM., Gursoy-OzdemirY., GurerG., and DalkaraT. (2004). Loss of NeuN immunoreactivity after cerebral ischemia does not indicate neuronal cell loss: a cautionary note. Brain Res. 1015, 169–174.
33.
LavezziA.M., CornaM.F., and MatturriL. (2013). Neuronal nuclear antigen (NeuN): A useful marker of neuronal immaturity in sudden unexplained perinatal death. J. Neurol. Sci., 329, 45–50.
34.
ChodobskiA., ZinkB.J., and Szmydynger-ChodobskaJ. (2011). Blood–brain barrier pathophysiology in traumatic brain injury. Transl. Stroke Res., 2, 492–516.
35.
HabgoodM.D., ByeN., DziegielewskaK.M., EkC.J., LaneM.A., PotterA., Morganti-KossmannC., and SaundersN.R. (2007). Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. Eur. J. Neurosci., 25, 231–238.
36.
ZobelK., HansenU., and GallaH.J. (2016). Blood-brain barrier properties in vitro depend on composition and assembly of endogenous extracellular matrices. Cell. Tissue Res., 365, 1–13.
37.
GentryL.R., ThompsonB., and GoderskyJ.C. (1988). Trauma to the corpus callosum: MR features. A.J.N.R. Am. J. Neuroradiol., 9, 1129–1138.
38.
Abdel-DayemH.M., Abu-JudehH., KumarM., AtayS., NaddafS., El-ZeftawyH., and LuoJ.Q. (1998). SPECT brain perfusion abnormalities in mild or moderate traumatic brain injury. Clin. Nucl. Med., 23, 309–317.
39.
MaxwellW.L. (2004). Differential responses in three thalamic nuclei in moderately disabled, severely disabled and vegetative patients after blunt head injury. Brain, 127, 2470–2478.
40.
RossD.T., GrahamD.I., and AdamsJ.H. (1993). Selective loss of neurons from the thalamic reticular nucleus following severe human head injury. J. Neurotrauma, 10, 151–165.
KlatzoI., WiśniewskiH., and SmithD.E. (1965). Observations on penetration of serum proteins into the central nervous system. Prog. Brain Res., 15, 73–88.
43.
MaasA.I.R., StocchettiN., and BullockR. (2008). Moderate and severe traumatic brain injury in adults. Lancet Neurol. 7, 728–741.
44.
RamlackhansinghA.F., BrooksD.J., GreenwoodR.J., BoseS.K., TurkheimerF.E., KinnunenK.M., GentlemanS., HeckemannR.A., GunanayagamK., GelosaG., and SharpD.J. (2011). Inflammation after trauma: microglial activation and traumatic brain injury. Ann. Neurol., 70, 374–383.
45.
HicksR., SoaresH., SmithD., and McIntoshT. (1996). Temporal and spatial characterization of neuronal injury following lateral fluid-percussion brain injury in the rat. Acta Neuropathol. 91, 236–246.
46.
BalançaB., BaptesteL., LieutaudT., RessnikoffD., GuyR., BezinL., and MarinescoS. (2016). Neuronal loss as evidenced by automated quantification of neuronal density following moderate and severe traumatic brain injury in rats. J. Neurosci. Res., 94, 39–49.
47.
SmithD.H., JohnsonV.E., and StewartW. (2013). Chronic neuropathologies of single and repetitive TBI: substrates of dementia?. Nat. Rev. Neurol., 9, 211–221.
48.
GaoX. and ChenJ. (2011). Mild traumatic brain injury results in extensive neuronal degeneration in the cerebral cortex. J. Neuropathol. Exp. Neurol., 70, 183–191.
49.
JohnsonV.E., and StewartW. (2015). Traumatic brain injury: age at injury influences dementia risk after TBI. Nat. Rev. Neurol., 11, 128–130.
50.
YeL., HuangY., ZhaoL., LiY., SunL., ZhouY., QianG., and ZhengJ.C. (2013). IL-1β and TNF-α induced neurotoxicity through glutamate production: a potential role for neuronal glutaminase. J. Neurochem., 125, 897–908.
51.
AdamsH., MitchellD.E., GrahamD.I., and DoyleD. (1977). Diffuse brain damage of immediate impact type. Its relationship to “primary brain-stem damage” in head injury. Brain, 100, 489–502.
52.
KelleyB.J., LifshitzJ., and PovlishockJ.T. (2007). Neuroinflammatory responses after experimental diffuse traumatic brain injury. J. Neuropathol. Exp. Neurol., 66, 989–1001.
53.
LafrenayeA.D., TodaniM., WalkerS.A., and PovlishockJ.T. (2015). Microglia processes associate with diffusely injured axons following mild traumatic brain injury in the micro pig. J. Neuroinflammation, 1–15.
54.
ShitakaY., TranH.T., BennettR.E., SanchezL., LevyM.A., DikranianK., and BrodyD.L. (2011). Repetitive closed-skull traumatic brain injury in mice causes persistent multifocal axonal injury and microglial reactivity. J. Neuropathol. Exp. Neurol., 70, 551–567.
55.
WoffordK.L., HarrisJ.P., BrowneK.D., BrownD.P., GrovolaM.R., MietusC.J., WolfJ.A., DudaJ.E., PuttM.E., SpillerK.L., and CullenD.K. (2017). Rapid neuroinflammatory response localized to injured neurons after diffuse traumatic brain injury in swine. Exp. Neurol.1–34.
56.
BennettR.E. and BrodyD.L. (2014). Acute reduction of microglia does not alter Axonal injury in a mouse model of repetitive concussive traumatic brain injury. J. Neurotrauma, 31, 1647–1663.
57.
PovlishockJ.T. and JenkinsL.W. (1995). Are the pathobiological changes evoked by traumatic brain injury immediate and irreversible?. Brain Pathol. 5, 415–426.
58.
HånellA., GreerJ.E., McGinnM.J., and PovlishockJ.T. (2015). Traumatic brain injury-induced axonal phenotypes react differently to treatment. Acta Neuropathol. 129, 317–332.
59.
HillC.S., ColemanM.P., and MenonD.K. (2016). Traumatic axonal injury: mechanisms and translational opportunities. Trends Neurosci. 1–14.
60.
ChenX.H., JohnsonV.E., UryuK., TrojanowskiJ.Q., and SmithD.H. (2009). A lack of amyloid β plaques despite persistent accumulation of amyloid β in axons of long-term survivors of traumatic brain injury. Brain Pathol. 19, 214–223.
61.
SmithD.H., JohnsonV.E., and StewartW. (2013). Chronic neuropathologies of single and repetitive TBI: substrates of dementia?. Nat. Rev. Neurol., 9, 211–221.
62.
JohnsonV.E., StewartW., and SmithD.H. (2013). Axonal pathology in traumatic brain injury. Exp. Neurol., 246, 35–43.
63.
AdamsR.A., BauerJ., FlickM.J., SikorskiS.L., NurielT., LassmannH., DegenJ.L., and AkassoglouK. (2007). The fibrin-derived γ 377–395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J. Exp. Med., 204, 571–582.
64.
PaulJ., StricklandS., and MelchorJ.P. (2007). Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J. Exp. Med., 204, 1999–2008.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
